Excessive Daytime Sleepiness Pipeline Insight

DelveInsight’s, “Excessive Daytime Sleepiness Pipeline Insight, 2026” report provides comprehensive insights about 11+ companies and 12+ pipeline drugs in Excessive Daytime Sleepiness pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Excessive Daytime Sleepiness Understanding

Excessive Daytime Sleepiness Overview

Excessive daytime sleepiness (EDS) is a common and debilitating condition characterized by an inability to maintain wakefulness and alertness during normal daytime activities. It is a significant public health concern and is associated with a wide range of sleep, neurological, psychiatric, cardiovascular, and respiratory disorders. EDS can substantially impair cognitive performance, daily functioning, and quality of life, while increasing the risk of occupational and motor vehicle accidents, highlighting the importance of timely diagnosis and effective management.

Excessive daytime sleepiness (EDS) can result from insufficient sleep, sleep disorders such as obstructive sleep apnea and narcolepsy, circadian rhythm disturbances, neurological and psychiatric disorders, and the use of certain medications. Medical conditions including cardiovascular, respiratory, and metabolic diseases may also contribute to EDS by disrupting normal sleep quality and wakefulness.

The pathophysiology of excessive daytime sleepiness involves disruption of the neural pathways that regulate the sleep–wake cycle. Alterations in neurotransmitter systems, particularly the orexin (hypocretin), histamine, dopamine, and norepinephrine pathways, impair the brain's ability to maintain wakefulness. In disorders such as narcolepsy, the loss of orexin-producing neurons results in persistent daytime sleepiness and impaired alertness.

The diagnosis of excessive daytime sleepiness is based on a detailed clinical history, assessment of sleep habits, and evaluation for underlying sleep or medical disorders. Standardized questionnaires, such as the Epworth Sleepiness Scale (ESS), are commonly used to assess symptom severity, while objective tests including the Multiple Sleep Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT) help confirm the diagnosis and determine its underlying cause.

Treatment of excessive daytime sleepiness focuses on managing the underlying cause and improving daytime alertness. Management may include lifestyle modifications, treatment of associated sleep disorders, and the use of wake-promoting agents such as orexin receptor agonists, histamine H3 receptor antagonists/inverse agonists, or other central nervous system stimulants, depending on the underlying condition.

"Excessive Daytime Sleepiness Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Excessive Daytime Sleepiness pipeline landscape is provided which includes the disease overview and Excessive Daytime Sleepiness treatment guidelines. The assessment part of the report embraces, in depth Excessive Daytime Sleepiness commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Excessive Daytime Sleepiness collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Excessive Daytime Sleepiness Pipeline Report Highlights

The Excessive Daytime Sleepiness companies and academics are working to assess challenges and seek opportunities that could influence Excessive Daytime Sleepiness R&D. The therapies under development are focused on novel approaches to treat/improve Excessive Daytime Sleepiness.

Excessive Daytime Sleepiness Emerging Drugs Analysis

This segment of the Excessive Daytime Sleepiness report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Excessive Daytime Sleepiness Emerging Drugs

Samelisant: Suven Life Sciences Limited

Samelisant is an investigational oral small-molecule developed by Suven Life Sciences Limited for the treatment of excessive daytime sleepiness. It is a highly selective histamine H3 receptor inverse agonist that enhances histaminergic neurotransmission by blocking inhibitory H3 autoreceptors. Its mechanism of action increases the release of histamine and other wake-promoting neurotransmitters, thereby improving wakefulness and reducing excessive daytime sleepiness. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Excessive Daytime Sleepiness.

ORX142: Centessa Pharmaceuticals (UK) Limited

ORX142 is an investigational oral small-molecule developed for the treatment of excessive daytime sleepiness. It is a selective orexin receptor 2 (OX2R) agonist designed to restore orexin signaling, a key pathway involved in regulating wakefulness and the sleep–wake cycle. By selectively activating OX2R, ORX142 promotes wakefulness and improves daytime alertness, offering a targeted therapeutic approach for disorders characterized by excessive daytime sleepiness. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Excessive Daytime Sleepiness.

Further product details are provided in the report……..

Excessive Daytime Sleepiness Drug Therapeutic Assessment

This segment of the report provides insights about the different Excessive Daytime Sleepiness drugs segregated based on following parameters that define the scope of the report, such as:

Major Excessive Daytime Sleepiness Players in Excessive Daytime Sleepiness

There are approx. 11+ key companies which are developing the therapies Excessive Daytime Sleepiness. The companies which have their Excessive Daytime Sleepiness drug candidates in the most advanced stage, i.e. Phase III include, Suven Life Sciences Limited, and others.

Excessive Daytime Sleepiness Clinical Trial Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Excessive Daytime Sleepiness Drug Route of Administration

Excessive Daytime Sleepiness pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Excessive Daytime Sleepiness Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Excessive Daytime Sleepiness Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Excessive Daytime Sleepiness Clinical Trial Activities

The Excessive Daytime Sleepiness pipeline report provides insights into different Excessive Daytime Sleepiness clinical trials within phase II, I, preclinical and discovery stage. It also analyses Excessive Daytime Sleepiness therapeutic drugs key players involved in developing key drugs.

Excessive Daytime Sleepiness Pipeline Development Activities

The Excessive Daytime Sleepiness clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Excessive Daytime Sleepiness drugs.

Excessive Daytime Sleepiness Pipeline Report Insights

• Excessive Daytime Sleepiness Pipeline Analysis
• Excessive Daytime Sleepiness Therapeutic Assessment
• Excessive Daytime SleepinessUnmet Needs
• Impact of Excessive Daytime Sleepiness Drugs

Excessive Daytime Sleepiness Pipeline Report Assessment

• Excessive Daytime Sleepiness Pipeline Product Profiles
• Excessive Daytime SleepinessTherapeutic Assessment
• Excessive Daytime SleepinessPipeline Assessment
• Excessive Daytime Sleepiness Inactive drugs assessment
• Excessive Daytime Sleepiness Market Unmet Needs

Key Questions Answered In The Excessive Daytime Sleepiness Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Excessive Daytime Sleepiness drugs?
• How many Excessive Daytime Sleepiness drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Excessive Daytime Sleepiness?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Excessive Daytime Sleepiness therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Excessive Daytime Sleepiness and their status?
• What are the key designations that have been granted to the emerging drugs?

Excessive Daytime Sleepiness Key Players

• Suven Life Sciences Limited
• Centessa Pharmaceuticals (UK) Limited
• Eisai Inc.
• Axsome Therapeutics, Inc.

Excessive Daytime Sleepiness Key Products

• Samelisant
• ORX142 
• E2086 
• AXS-12